Status:
ACTIVE_NOT_RECRUITING
Preventing Cognitive Decline with Metformin
Lead Sponsor:
Garvan Institute of Medical Research
Collaborating Sponsors:
National Health and Medical Research Council, Australia
Conditions:
Cognitive Decline
Eligibility:
All Genders
60-80 years
Phase:
PHASE3
Brief Summary
A randomised control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.
Detailed Description
A randomised placebo-control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline, neuroimaging and biomarkers over 3 yea...
Eligibility Criteria
Inclusion
- overweight or obese (body mass index \>25.0 kg/m2, waist: women\>80 cm, men\>94cm;
- Mild cognitive impairment (Mild Neurocognitive Disorder), based on DSM-5 criteria;
- Fasting blood glucose \<7.0 mmol/L and HbA1c \<6.5%;
- Able to undertake neurocognitive testing in English.
- Not participating in another trial of drugs or lifestyle modification to reduce cognitive decline.
Exclusion
- Life-threatening illnesses to preclude participation in a 3-year study;
- Contraindications to the use of metformin (severe heart failure or eGFR \<40).
Key Trial Info
Start Date :
July 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2027
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT04511416
Start Date
July 15 2022
End Date
December 1 2027
Last Update
October 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Garvan Institute of Medical Research
Sydney, New South Wales, Australia, 2010